DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Fibrate
Fibrate
Lipid Lowering Agents, Cognitive Decline, and Dementia: the Three-City Study
Stems for Nonproprietary Drug Names
The Effects of Statin and Fibrate Drugs on Cholesterol Metabolism And
Lipid Management Protocol
1 Lipid Lowering Agents, Cognitive Decline, and Dementia
UMHS Guideline Screening and Management of Lipids
Metabolic Regulation by Lipid Activated Receptors by Maxwell A
Global Hypercoagulability in Patients with Schizophrenia Receiving Long-Term Antipsychotic Therapy
Repression of Glucocorticoid-Stimulated Angiopoietin-Like 4 Gene Transcription by Insulin
Treatment Strategy for Dyslipidemia in Cardiovascular Disease Prevention: Focus on Old and New Drugs
NLA Task Force on Statin Safety - 2014 Update
STATIN-FIBRATE REPORT: Focus on Safety VHA Pharmacy Benefits Management-Strategic Healthcare Group and the Medical Advisory Panel
Borderline Hypercholesterolaemia: When to Introduce Drugs D
Lipid Lowering Agents Are Associated with a Slower Cognitive Decline In
WO 2010/068601 Al
PPARA Polymorphism Influences the Cardiovascular Benefit Of
Redalyc.Utilisation of Atypical Antipsychotic Drugs in Institutionalised Elderly Persons and Prevalence of Metabolic Alterations
Current P SYCHIATRY
Top View
Antidiabetic Action of Bezafibrate in a Large Observational Database
Therapeutic Substitution
Add a Fibrate to a Statin?
Metformin Cuts BMI in At-Risk Teens
Fenofibrate-Induced Myopathy
Zetia® (Ezetimibe) Tablets
Gemfibrozil May 2012
Diabetic Retinopathy Tx: a Role for Fibrates and Statins?
UC Berkeley UC Berkeley Electronic Theses and Dissertations
The Effect of Bezafibrate in Preventing Glucolipid Abnormalities Induced by the Antipsychotic Risperidone
KDIGO Clinical Practice Guideline for Lipid Management in Chronic Kidney Disease
Therapeutic Class Overview Bile Acid Sequestrants
No Proof Fibrate Drugs Reduce Heart Risk in Diabetes Patients on Statins 10 August 2011
Emerging Strategies of Targeting Lipoprotein Lipase for Metabolic and Cardiovascular Diseases
Lipid-Lowering Drugs and Risk of New- Onset Diabetes: a Cohort Study Using Japanese Healthcare Data Linked to Clinical Data for Health Screening
Protocol for a Pharmacogenomic Study on Individualised Antipsychotic Drug Treatment for Patients with Schizophrenia
Medicines for Your Heart
Glycyrrhizic Acid Improved Lipoprotein Lipase Expression, Insulin Sensitivity
Bile Acid Sequestrants • Niacin • Fibrates • Mipomersen • Lomitapide • LDL Apheresis Evidence for Treating All FH Patients
ESC/EAS Guidelines for the Management of Dyslipidemias
What Are Effective Medication Combinations for Dyslipidemia?
Mediterranean Diet and Physical Activity Decrease the Initiation of Cardiovascular Drug Use in High Cardiovascular Risk Individuals: a Cohort Study
Management of Hypertriglyceridemia: Common Questions and Answers
Evidence of Direct Smooth Muscle Relaxant Effects of the Fibrate Gemfibrozil
Primary Prevention with Lipid Lowering Drugs and Long Term Risk of Vascular Events in Older People
Statins, Fibrates, and Other Peroxisome Proliferator-Activated Receptor Agonists for the Treatment of Cholestatic Liver Diseases
2. Cardiovascular System
Management of Hypertriglyceridemia BMJ: First Published As 10.1136/Bmj.M3109 on 12 October 2020
Management of Hypertriglyceridemia BMJ: First Published As 10.1136/Bmj.M3109 on 12 October 2020
(12) United States Patent (10) Patent No.: US 8,901,114 B2 B0ehme Et Al
Lipotoxicity and Diabetic Nephropathy: Novel Mechanistic Insights and Therapeutic Opportunities
Hypoglycemic Drug Interactions See Also Chart, Page 2
Lipid Lowering Agents Evidence, Questions & Comparisons The
Medical Compliance of Fibrate and the Decreased Risk of Age-Related Macular Degeneration in Dyslipidemia-Related Diseases: a Population-Based Cohort Study
Safety of High Dose Statin-Fibrate Combinations
TRICOR (Fenofibrate) Tablet, for Oral Use • TRICOR Can Increase Serum Transaminases
Appropriate Statin Therapy